Present and Future of Personalised Medicine for Endocrine Cancers

• Autres auteurs: Ronchi, Cristina L. (Éditeur intellectuel), Altieri, Barbara (Éditeur intellectuel)
• Format: Électronique Chapitre de livre
• Langue: anglais
• Publié: Basel MDPI - Multidisciplinary Digital Publishing Institute 2022
• Sujets: Medicine; papillary thyroid cancer; SUV PET/CT; BRAF V600E; immune checkpoint inhibitors (ICIs); ipilimumab; nivolumab; prolactinoma; Cushing's disease; aggressive pituitary tumor; aggressive PitNET; aggressive pituitary adenoma; pituitary carcinoma; adrenocortical cancer; adrenal adenomas; adrenal tumors; p53; p27; ki-67; reticulin; mitotane; adjuvant treatment; recurrence; recurrence free survival; timing; intratumoral heterogeneity; thyroid tumor; BRAF; RET/PTC rearrangements; RAS mutation; adrenal cortex; carcinoma; angiogenesis; gene expression; osteopontin; hyaluronan synthase 1; multikinase inhibitors; sorafenib; lenvatinib; differentiated thyroid cancer; radioiodine resistance; predictive marker; predictors; response to treatment; survival; information needs and preferences; focus group interview; personalized medicine; neuroendocrine tumours; phaeochromocytoma; paraganglioma; molecular clusters; n/a
• Accès en ligne: DOAB: download the publication; DOAB: description of the publication

Major technological advances in genomics have made it possible to identify critical genetic alterations in cancer, rendering oncology well along the path to "personalised cancer medicine". Thanks to developments in genetics, several mutations and gene rearrangements have been identified in...